Lv4
504 积分 2025-01-08 加入
Chemoproteomics-guided development of SLC15A4 inhibitors with anti-inflammatory activity
1个月前
已完结
Solute carrier family 15 member 4, an emerging therapeutic target for systemic lupus erythematosus
1个月前
已完结
Zanidatamab with and without Tislelizumab in HER2-Positive Gastroesophageal Cancer
1个月前
已完结
Zanidatamab with and without Tislelizumab in HER2-Positive Gastroesophageal Cancer
1个月前
已完结
Daraxonrasib in Previously Treated Advanced RAS -Mutated Pancreatic Cancer
1个月前
已完结
Trastuzumab deruxtecan in patients with HER2-positive advanced colorectal cancer (DESTINY-CRC02): primary results from a multicentre, randomised, phase 2 trial
3个月前
已完结
Trastuzumab deruxtecan in patients with HER2-positive advanced colorectal cancer (DESTINY-CRC02): primary results from a multicentre, randomised, phase 2 trial
3个月前
已完结
Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial
3个月前
已完结
Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial
3个月前
已完结
Discovery of a Series of Potent, Selective, and Orally Bioavailable Nucleoside Inhibitors of CD73 That Demonstrates In Vivo Antitumor Activity
4个月前
已完结
皖公网安备34019202002308
